Evaluate IO therapy response before treatment begins. 

Use your patient's live tumor to guide therapy selection. 

Order eLIVE Now
eLIVE_logo_RGB

What is eLIVE?

eLIVE is a Laboratory Developed Test (LDT) that uses cytokine profiling from a live tumor biopsy to predict a patient's likelihood of response to an immune checkpoint inhibitor (ICI).

How it works

A licensed clinician submits an order for eLIVE. Elephas Laboratories will then ship a proprietary collection kit to the facility where the biopsy will be performed. 
collect

Collect

Collect biopsy. Follow proprietary collection kit protocol to maintain live tumor microenvironment.

ship

Ship

Send live biopsy to Elephas Laboratories where the sample's response is assessed following exposure to treatment.

result

Result

Receive tumor response profile and pathologist interpretation within 14 days .

83% of surveyed oncologists said that the greatest challenge in predicting ICI response is variability in patient outcomes.

Market survey conducted by Elephas, Sept 2025

Ready to order?

eLIVE is currently available to licensed healthcare providers only.
Patients seeking eLIVE should contact their clinicians. 

Order online

Order via our secure, HIPAA-compliant order management system. 

Access Ordering Portal

Email or eFax

Download the order form. Complete and return via secure email or fax to (855) 350-1433.

Download Order Form

Contact eLIVE support with questions.

Elephas Laboratories CLIA #52D2333937
Laboratory Operating Hours: Monday to Friday: 8:00 a.m. to 5:00 p.m. CT.

Phone: (608) 622-7954 | Email: elive@elephaslabs.com

A dedicated support team is available Monday to Friday from 8:00 a.m. to 6:00 p.m. CT.

References: 1.  Ramasubramanian, T.S.  Adstamongkonkul, P., Scribano, C., et al. A live tumor fragment platform to assess immunotherapy response in core needle biopsies while addressing challenges of tumor heterogeneity. J Transl Med 24, 18 (2026). https://doi.org/10.1186/s12967-025-07378-2  2.  Voabil P, de Bruijn M, Roelofsen LM, et al. An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer. Nature medicine. 2021;27(7):1250-1261. doi:10.1038/s41591-021-01398-3